XML 44 R27.htm IDEA: XBRL DOCUMENT v3.3.1.900
Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables)
 12 Months Ended
Dec. 31, 2015
Accounting Policies [Abstract]  
Property, Plant and Equipment Estimated Ranges of Useful Lives
Depreciation is calculated on a straight-line basis over the following estimated ranges of useful lives: 
Asset classification
  
Estimated useful life
Plant equipment
  
5 – 20 years
Lab equipment
  
3 – 7 years
Leasehold improvements
  
Shorter of useful life
or life of lease
Building and improvements
  
7 – 20 years
Computer equipment and software
  
3 – 7 years
Furniture and fixtures and automobiles
  
5 – 7 years
Reconciliation of Other Significant Reconciling Items from Segments to Consolidated
A reconciliation of total gross margin to operating loss is as follows (in thousands):
 
Year ended December 31,
 
2015
 
2014
 
2013
Gross margin
$
15,121

 
$
16,734

 
$
13,577

Research and development programs revenue
12,831

 
23,045

 
19,788

Research and development expense
48,094

 
81,680

 
66,572

Sales, general and administrative expense
80,733

 
90,266

 
62,933

Restructuring charges
4,953

 
3,514

 
—

Loss from operations
$
(105,828
)
 
$
(135,681
)
 
$
(96,140
)
Schedule of Segment Reporting Information, by Segment
The following table reflects revenues and gross margins for the Company's operating segments for the years ended December 31, 2015, 2014 and 2013, reconciled to the Company’s total product revenue and cost of product revenue as shown in its consolidated statements of operations (in thousands):
Year ended December 31, 2015
Algenist®
 
Ingredients & Other
 
Total
Product revenue
$
23,278

 
$
10,022

 
$
33,300

Cost of product revenue
7,616

 
10,563

 
18,179

Segment gross margin
$
15,662

 
$
(541
)
 
$
15,121

Year ended December 31, 2014
 
 
 
 
 
Product revenue
$
24,429

 
$
12,917

 
$
37,346

Cost of product revenue
7,746

 
12,866

 
20,612

Segment gross margin
$
16,683

 
$
51

 
$
16,734

Year ended December 31, 2013
 
 
 
 
 
Product revenue
$
19,856

 
$
106

 
$
19,962

Cost of product revenue
6,338

 
47

 
6,385

Segment gross margin
$
13,518

 
$
59

 
$
13,577
Schedule of Accumulated Other Comprehensive Income (Loss)
Accumulated Other Comprehensive Loss—The components of accumulated other comprehensive income loss consisted of the following (in thousands):
 
Foreign Currency Translation Adjustments
 
Change in unrealized gain/loss on available-for-sale securities
 
Total Accumulated Other Comprehensive Loss
Balance at December 31, 2012
$
(725
)
 
$
326

 
$
(399
)
Current period other comprehensive loss
(3,155
)
 
(240
)
 
(3,395
)
Balance at December 31, 2013
(3,880
)
 
86

 
(3,794
)
Current period other comprehensive loss
(6,908
)
 
(312
)
 
(7,220
)
Balance at December 31, 2014
(10,788
)
 
(226
)
 
(11,014
)
Current period other comprehensive loss
(11,545
)
 
228

 
(11,317
)
Balance at December 31, 2015
$
(22,333
)
 
$
2

 
$
(22,331
)
Calculation of Basic and Diluted Net Loss Per Share
The following table summarizes the Company’s calculation of basic and diluted net loss per share (in thousands, except share and per share amounts):  
 
Year ended December 31,
 
2015
 
2014
 
2013
Numerator
 
 
 
 
 
Net loss
$
(141,447
)
 
$
(162,141
)
 
$
(116,389
)
Denominator
 
 
 
 
 
Weighted-average number of common shares used in net loss per share calculation
80,165,402

 
75,879,721

 
64,228,387

Less: Weighted-average shares subject to repurchase
—

 
(513
)
 
(16,429
)
Denominator: basic and diluted
80,165,402

 
75,879,208

 
64,211,958

Net loss per share, basic and diluted
$
(1.76
)
 
$
(2.14
)
 
$
(1.81
)
Outstanding Shares of Potentially Dilutive Securities Excluded from Calculation of Dilutive Net Loss per Share
The following outstanding shares of potentially dilutive securities were excluded from the calculation of diluted net loss per share for the periods presented as the effect was anti-dilutive:
 
Year ended December 31,
 
2015
 
2014
 
2013
Options to purchase common stock
11,900,671

 
13,740,204

 
9,957,367

Common stock subject to repurchase
—

 
—

 
2,942

Restricted stock units
1,883,552

 
1,812,332

 
1,871,907

Warrants to purchase common stock
750,000

 
1,250,000

 
1,385,000

Shares of common stock to be issued upon conversion of the Notes
18,790,996

 
18,790,996

 
9,905,521

Total
33,325,219

 
35,593,532

 
23,122,737